Introduction
The pre-clinical study of GXNPC1® has shown the preconditioned stem cells highly express factors associated with angiogenesis, inflammation reduction, and neural differentiation, and can improve stroke-induced disabilities in mice by enhancing coordination, balance, or mobility.
According to the GXNPC1® Phase Ⅱ clinical trial, subjects receiving GXNPC1® treatment demonstrated motor recovery within 2 weeks. In the high-dose group, the National Institutes of Health Stroke Scale (NIHSS) score improved by an average of 1.2 points at Week 2 and continued to improve to an average of 2.7 points by Week 24. Furthermore, 89% of patients showed improvement in functional and behavioral assessments following treatment.
Additionally, in Phase I&II clinical trials, no safety issues related to GXNPC1® (i.e., SUSAR) were observed during the follow-up period, proving GXNPC1® is well tolerated.
Features / strengths
． Novel technology & product (first-in-class medicine)
．Autologous ADSCs
．Leading stem cell therapy in chronic stroke, moving forward to clinical trial Phase III
．Intracerebral (IC) injection
．The clinical outcomes of clinical trial have been published (J Tissue Eng Regen Med. 2022;16(1):3-13. doi:10.1002/term.3256)
Specification in detail
Material
Adipose-derived stem cells (ADSCs)
Indication
Chronic stroke
Administration
Intracerebroventricular injection
Product Status:
Phase III
Supporting document
